Healthcare & Pharmaceutical Market Research in Argentina

BioNixus is a leading healthcare market research company in Argentina, delivering CEI-compliant HCP surveys, KOL mapping, and payer landscape research aligned with ANMAT and CONETEC requirements. BioNixus combines primary research depth with physician access across major Argentine academic medical centres and specialist community networks — in Spanish and English.

A healthcare market research company in Argentina designs and executes studies covering physician prescribing behaviour, obra social and prepaga payer access dynamics, patient journeys, KOL influence mapping, and competitive landscape intelligence — for pharmaceutical, biotech, and medical device companies launching or growing in the Argentine market.

Argentina has a fragmented, three-tier healthcare system rather than a single national payer. Coverage runs through obras sociales (union and employer-linked social insurance funds), PAMI (the retiree and pensioner insurance programme), private prepagas (voluntary private health plans), and a public hospital network that is free at the point of use. ANMAT market authorisation does not guarantee reimbursement — commercial outcomes depend on negotiations with individual obras sociales and prepagas, PAMI formulary decisions, and increasingly on CONETEC health technology assessment recommendations feeding into public and social security purchasing.

BioNixus covers oncology and hematology, immunology and biologics (including biosimilar uptake across obras sociales and prepagas), cardiovascular, diabetes and metabolic (including GLP-1), rare disease, respiratory, infectious disease, neurology, medical devices, and consumer health across the Argentine market.

Yes. BioNixus maintains physician and specialist networks across major Argentine academic and clinical centres including Hospital Italiano de Buenos Aires, Instituto de Oncología Ángel H. Roffo, and Universidad de Buenos Aires-affiliated teaching hospitals. For scarce specialties such as oncology or rare disease, we recruit through national cancer centre networks and rare disease specialist directories, spanning both public hospital and private prepaga-affiliated practice settings.

Focused HCP surveys complete in 3–4 weeks. Full mixed-method programmes including payer depth interviews across obras sociales and prepagas, plus advisory board modules, typically run 6–10 weeks depending on therapy area, CEI ethics review requirements, and respondent scarcity. Oncology and rare disease KOL programmes with multi-centre recruitment across Buenos Aires and other provinces may require extended planning timelines.

Yes. BioNixus designs and executes Argentine patient research in compliance with Ley de Protección de Datos Personales 25.326 data privacy standards and CEI (Comités de Ética en Investigación) research ethics requirements. All patient and caregiver research involves documented informed consent, de-identified reporting, and secure data handling consistent with national privacy legislation.

Yes. Argentine modules can run with comparable cells in the USA, UK, EU5 (Germany, France, Italy, Spain), Brazil, Saudi Arabia, and UAE — using consistent instruments for global portfolio committees managing multi-market access strategy from one research partner.